CVS HEALTH Corp (CVS)
Health Care · Health Care Services · US stock · S&P 500 component
$92.36
▼ -0.22 (0.24%)
Fair valueFair
$112 +21.6% to fair value
$56fair band $79–$146$169
Day's range
$92.05 – $93.35
52-week range
$68.48 – $110.00
About CVS HEALTH Corp
CVS Health combines a large pharmacy chain, a pharmacy benefit manager, a health insurer and a growing set of care delivery services. Customers fill prescriptions at its stores, employers and health plans use its benefit management services, and Aetna covers members with health insurance. Revenue is generated from prescription sales, insurance premiums and service fees, and results depend on medical costs, drug pricing and reimbursement rates.
The company reported trailing revenue of $415.1 billion and three-year growth of 7.6% a year. Profitability figures show an operating margin of 2.0% and a return on invested capital of 6%. Its net debt to EBITDA ratio stands at 3.7 times. The dividend yield is 2.9%. Its X-Ray Score is 51 out of 100. The figures are a snapshot of reported results rather than a forecast.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $68.48 – $110.00Volume 6,980,700Daily, split-adjusted
Vitals
Market cap$118.9B
52-week range$68.48 – $110.00
Volume (last day)6,980,700
P/E (TTM)24.1
EBIT / EV yield5.0%
Free-cash-flow yield9.9%
Dividend yield2.9%
Revenue (TTM)$415.1B
Net income (TTM)$4.9B
Operating margin2.0%
Return on capital5.5%
Debt incl. leases$61.4B
Cash & securities$14.0B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$112model spread $107 – $118
Fair
+21.6% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $92
Undervalued < $79Fair $79 – $146Overvalued > $146
10-year DCF (market-scaled)
$82
Peer multiples
$120
Earnings power floor (not blended)
$57
Fundamentals-adjusted multiple
$135
Growth the price implies
12.3%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Strong
78/100
Cheap against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield5.0%
Free-cash-flow yield9.9%
Fair value vs price1.2×
Growth
Weak
40/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)7.6%
EPS growth (3y)-24.7%
Growth consistency100%
Profitability
Weak
49/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital5.5%
Operating margin2.0%
Gross profitability72.8%
Financial health
Weak
29/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score7 / 9
Net debt / EBITDA3.7×
Interest cover2.7×
Dividends
Fair
64/100
Dividend is typical for its sector.
See the numbers →
Dividend yield2.9%
Dividends vs free cash flow29%
Dividend growth5.3%
Quarterly results: last 6 quarters
+7.0%
Mar '25
+8.4%
Jun '25
+7.8%
Sep '25
+8.2%
Dec '25
+6.2%
Mar '26
+7.3%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $106.1B, diluted EPS $2.31.
Compare with peers
DVA Davita Inc.66 CI Cigna Group66 DGX Quest Diagnostics Inc57 LH Labcorp Holdings Inc.46Other Health Care Services companies by X-Ray Score.
Fundamentals checklist
● 5 Good · ● 3 Average · ● 8 BadCash quality
Earnings backed by cashAverage
Free-cash-flow yieldGood
Risk models
Altman Z''Bad
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Bad
Free-cash-flow growth (3y)Bad
Revenue growth (3y)Average
Growth consistencyGood
Balance sheet
Current ratioBad
Net debt / EBITDABad
Interest coverBad
Valuation
Fair value vs priceGood
EBIT / EV yieldGood
Profitability
Return on invested capitalBad
Operating marginBad
Gross profitabilityGood
Each check is graded against the company's sector, not a fixed number. Checklist score 46/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $292.1B | $322.5B | $357.8B | $372.8B | $402.1B |
| Operating income | $13.3B | $8.0B | $13.7B | $8.5B | $4.7B |
| Net income | $8.0B | $4.3B | $8.3B | $4.6B | $1.8B |
| Operating cash flow | $18.3B | $16.2B | $13.4B | $9.1B | $10.6B |
| Operating margin | 4.6% | 2.5% | 3.8% | 2.3% | 1.2% |
| Free cash flow | $15.7B | $13.5B | $10.4B | $6.3B | $7.8B |
| Diluted EPS | $6.02 | $3.26 | $6.47 | $3.66 | $1.39 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
10 bullish · 1 neutral · 5 bearish
Weekly
Strongly bullish
9 bullish · 1 neutral · 2 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 88.60 | Bullish |
| EMA 10 | 89.39 | Bullish |
| SMA 20 | 87.65 | Bullish |
| EMA 20 | 89.25 | Bullish |
| SMA 50 | 91.73 | Bullish |
| EMA 50 | 91.63 | Bullish |
| SMA 100 | 96.52 | Bearish |
| EMA 100 | 92.11 | Bullish |
| SMA 200 | 87.51 | Bullish |
| EMA 200 | 88.15 | Bullish |
Oscillators (daily)
| RSI (14) | 58.18 | Neutral |
| MACD (12, 26) | -0.49 | Bearish |
| Momentum (12) | 7.78 | Bullish |
| Stochastic %K (14) | 89.14 | Bearish |
| Williams %R (14) | -10.86 | Bearish |
| CCI (20) | 243.8 | Bearish |
Pivot points (classic, last session)
S3 90.52 | S2 91.29 | S1 91.82 | Pivot 92.59 | R1 93.12 | R2 93.89 | R3 94.42 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
2.66 USD
Yield on today's price
2.88%
Frequency
Quarterly
Next ex-dividend date
22 Oct 2026
| Ex-dividend date | Amount per share |
|---|---|
| 22 Oct 2026 (upcoming) | 0.6650 |
| 23 Jul 2026 | 0.6650 |
| 23 Apr 2026 | 0.6650 |
| 22 Jan 2026 | 0.6650 |
| 23 Oct 2025 | 0.6650 |
| 22 Jul 2025 | 0.6650 |
| 22 Apr 2025 | 0.6650 |
| 23 Jan 2025 | 0.6650 |
| 21 Oct 2024 | 0.6650 |
| 22 Jul 2024 | 0.6650 |
| 19 Apr 2024 | 0.6650 |
| 19 Jan 2024 | 0.6650 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
CVS SEC filings
17 Aug 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
5 Aug 2026
10-QSEC EDGAR
Quarterly report
5 Aug 2026
8-KSEC EDGAR
Results of operations
18 May 2026
8-KSEC EDGAR
Director or officer change; Shareholder vote results
6 May 2026
10-QSEC EDGAR
Quarterly report
6 May 2026
8-KSEC EDGAR
Results of operations
3 Apr 2026
DEF 14ASEC EDGAR
Proxy statement
19 Mar 2026
8-KSEC EDGAR
Director or officer change
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.